Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography

Application to the evaluation of CYP2D6 drug interactions

Adrián LLerena, R. Berecz, Pedro Dorado, César Sanz De la Garza, María Jesús Norberto, Macarena Cáceres, José Ramón Gutiérrez

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

A high-pressure liquid chromatography with ultra-violet detection method for the simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma after liquid-liquid extraction has been developed. The limit of quantitation was 5 nmol/L, and the inter-day coefficient of variation was less than 8% for both compounds. The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively. Studies of analytical interference showed that the most commonly co-administered antidepressants and benzodiazepines did not interfere. The method was used for the determination of the plasma concentrations of a schizophrenic patient treated daily with an oral dose of 4.5 mg risperidone. The patient suffered severe extrapyramidal side-effects after adding risperidone to his previous medication of haloperidol and levomepromazine. The risperidone plasma concentration was well above the average (182 nmol/L), which suggests that a pharmacokinetic interaction occurred, presumably due to inhibition of the enzyme CYP2D6.

Original languageEnglish
Pages (from-to)213-219
Number of pages7
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume783
Issue number1
DOIs
Publication statusPublished - Jan 5 2003

Fingerprint

Drug interactions
Plasma (human)
Cytochrome P-450 CYP2D6
Risperidone
Liquid chromatography
Drug Interactions
Liquid Chromatography
Plasmas
Methotrimeprazine
High pressure liquid chromatography
Liquid-Liquid Extraction
Pharmacokinetics
Liquids
Haloperidol
Benzodiazepines
Antidepressive Agents
High Pressure Liquid Chromatography
Paliperidone Palmitate
Recovery
Enzymes

Keywords

  • 9-Hydroxyrisperidone
  • CYP2D6
  • Risperidone

ASJC Scopus subject areas

  • Biochemistry

Cite this

Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography : Application to the evaluation of CYP2D6 drug interactions. / LLerena, Adrián; Berecz, R.; Dorado, Pedro; De la Garza, César Sanz; Norberto, María Jesús; Cáceres, Macarena; Gutiérrez, José Ramón.

In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 783, No. 1, 05.01.2003, p. 213-219.

Research output: Contribution to journalArticle

LLerena, Adrián ; Berecz, R. ; Dorado, Pedro ; De la Garza, César Sanz ; Norberto, María Jesús ; Cáceres, Macarena ; Gutiérrez, José Ramón. / Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography : Application to the evaluation of CYP2D6 drug interactions. In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2003 ; Vol. 783, No. 1. pp. 213-219.
@article{2983b9cb127b450792fef5c6ba117532,
title = "Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: Application to the evaluation of CYP2D6 drug interactions",
abstract = "A high-pressure liquid chromatography with ultra-violet detection method for the simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma after liquid-liquid extraction has been developed. The limit of quantitation was 5 nmol/L, and the inter-day coefficient of variation was less than 8{\%} for both compounds. The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4{\%}, with an intra-day coefficient of variation of under 5 and 6{\%}, respectively. Studies of analytical interference showed that the most commonly co-administered antidepressants and benzodiazepines did not interfere. The method was used for the determination of the plasma concentrations of a schizophrenic patient treated daily with an oral dose of 4.5 mg risperidone. The patient suffered severe extrapyramidal side-effects after adding risperidone to his previous medication of haloperidol and levomepromazine. The risperidone plasma concentration was well above the average (182 nmol/L), which suggests that a pharmacokinetic interaction occurred, presumably due to inhibition of the enzyme CYP2D6.",
keywords = "9-Hydroxyrisperidone, CYP2D6, Risperidone",
author = "Adri{\'a}n LLerena and R. Berecz and Pedro Dorado and {De la Garza}, {C{\'e}sar Sanz} and Norberto, {Mar{\'i}a Jes{\'u}s} and Macarena C{\'a}ceres and Guti{\'e}rrez, {Jos{\'e} Ram{\'o}n}",
year = "2003",
month = "1",
day = "5",
doi = "10.1016/S1570-0232(02)00661-X",
language = "English",
volume = "783",
pages = "213--219",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography

T2 - Application to the evaluation of CYP2D6 drug interactions

AU - LLerena, Adrián

AU - Berecz, R.

AU - Dorado, Pedro

AU - De la Garza, César Sanz

AU - Norberto, María Jesús

AU - Cáceres, Macarena

AU - Gutiérrez, José Ramón

PY - 2003/1/5

Y1 - 2003/1/5

N2 - A high-pressure liquid chromatography with ultra-violet detection method for the simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma after liquid-liquid extraction has been developed. The limit of quantitation was 5 nmol/L, and the inter-day coefficient of variation was less than 8% for both compounds. The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively. Studies of analytical interference showed that the most commonly co-administered antidepressants and benzodiazepines did not interfere. The method was used for the determination of the plasma concentrations of a schizophrenic patient treated daily with an oral dose of 4.5 mg risperidone. The patient suffered severe extrapyramidal side-effects after adding risperidone to his previous medication of haloperidol and levomepromazine. The risperidone plasma concentration was well above the average (182 nmol/L), which suggests that a pharmacokinetic interaction occurred, presumably due to inhibition of the enzyme CYP2D6.

AB - A high-pressure liquid chromatography with ultra-violet detection method for the simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma after liquid-liquid extraction has been developed. The limit of quantitation was 5 nmol/L, and the inter-day coefficient of variation was less than 8% for both compounds. The mean recoveries of risperidone and 9-hydroxyrisperidone added to plasma were 96.8 and 99.4%, with an intra-day coefficient of variation of under 5 and 6%, respectively. Studies of analytical interference showed that the most commonly co-administered antidepressants and benzodiazepines did not interfere. The method was used for the determination of the plasma concentrations of a schizophrenic patient treated daily with an oral dose of 4.5 mg risperidone. The patient suffered severe extrapyramidal side-effects after adding risperidone to his previous medication of haloperidol and levomepromazine. The risperidone plasma concentration was well above the average (182 nmol/L), which suggests that a pharmacokinetic interaction occurred, presumably due to inhibition of the enzyme CYP2D6.

KW - 9-Hydroxyrisperidone

KW - CYP2D6

KW - Risperidone

UR - http://www.scopus.com/inward/record.url?scp=0037419494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037419494&partnerID=8YFLogxK

U2 - 10.1016/S1570-0232(02)00661-X

DO - 10.1016/S1570-0232(02)00661-X

M3 - Article

VL - 783

SP - 213

EP - 219

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 1

ER -